But in 1992 Abbott Laboratories' temafloxacin, marketed as Omniflox, was withdrawn after only three months following 50 severe cases of adverse reaction, including three deaths. In 1999, 14 cases of acute liver failure, including five deaths, were linked to Pfizer's drug trovafloxacin, marketed as Trovan, prompting the FDA to severely limit its use. Later that year, Glaxo Wellcome's grepafloxacin, marketed as Raxar, was withdrawn after reports of heart rhythm abnormalities, with seven deaths.